16 March 2016 - This Viewpoint describes the rationale behind an FDA and NIH effort to develop a glossary of common terms and definitions for biomarkers and surrogate endpoints.

For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2503184&utm_source=Silverchair_Information_Systems&utm_campaign=Tuesday_March_15_2016&utm_content=etoc&cmp=1&utm_medium=email